source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

Arcis Biotechnology raises £1.25 million and opens further £0.5 million investment opportunity through Capital Cell

Arcis Biotechnology logo 25.10.18Capital Cell logo 15.11.18UK-based nucleic acid sample preparation specialist Arcis Biotechnology has closed a £1.25 million investment round and made a decision to overfund by an additional £0.5 million via specialist life sciences equity crowdfunding platform Capital Cell. Arcis will use the funds to expand its innovative product range and to support the continued growth of the company.

The £1.25 million in funding was secured from existing and new investors, based on a pre-money valuation of £18.2 million. Following its recent development successes in the isolation and preservation of microRNA (miRNA) and oncology biomarkers, Arcis is now looking to invest further in R&D and product development, and to drive international business expansion. Arcis has stated tthat the additional £0.5 million from the Capital Cell funding round will underpin the company’s projected revenue growth and its associated working capital requirements over the next two years. Previous investments in Arcis include an over-subscribed £2.5 million investment round in January 2016, and £160,000 under Innovate UK’s Biocatalyst programme.

For further information about Arcis Biotechnology visit and for further information about Capital Cell visit

Last modified onThursday, 15 November 2018 08:48

Related items

Latest from Tom Mulligan